Long term augmentation with T3 in refractory major depression

BackgroundThe addition of triiodothyronine (T3) is one of the most widely studied augmentation strategies for refractory depression. Despite this there are no long term studies or studies of doses above 100 mcg.MethodLong term and high dose augmentation with T3 for refractory unipolar major depression was studied. Seventeen patients were assessed for symptom improvement with the Clinical Global Impression of Improvement Scale.ResultsFourteen of 17 patients showed improvement. One patient saw no improvement and 2 dropped out due to side effects. The patients who benefited showed an average CGI improvement of 2.5 (SD: 0.52). The average dose used was 80 mcg (SD: 30.2, range: 25 mcg-150 mcg). The average length of time on T3 was 24.2 months (SD: 19.4, range: 11.8-86.7). This case series shows that T3 may be successfully employed as a long term treatment augmentation of major depression if over time dosage levels are increased beyond the traditional 50 mcg.